MicroDose intends to submit the investigational new drug (IND) reactivation with the US Food and Drug Administration and to begin MDT-637Phase I study this year.
As per the terms of the agreement, MicroDose is entitled to get upfront payment from Gilead.
Gilead will provide research funding to support MicroDose’s continued development of MDT-637 through Phase IIa clinical trials.
Gilead will also responsible to pay additional payments to MicroDose based upon the achievement of certain development, regulatory and commercial milestones, as well as development fees and royalties on future potential net sales.
Gilead Research and Development executive vice president and chief scientific officer Norbert Bischofberger said they believe this program aligns well with their expertise in both antiviral and respiratory drug development and they look forward to working with the MicroDose team to advance MDT-637 into clinical testing.